HK1110512A1 - Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder - Google Patents
Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorderInfo
- Publication number
- HK1110512A1 HK1110512A1 HK08101377.3A HK08101377A HK1110512A1 HK 1110512 A1 HK1110512 A1 HK 1110512A1 HK 08101377 A HK08101377 A HK 08101377A HK 1110512 A1 HK1110512 A1 HK 1110512A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- bombesin
- gastrin
- treatment
- inflammatory conditions
- bipolar disorder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
- A61K38/105—Bombesin; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2207—Gastrins; Cholecystokinins [CCK]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Arc Welding In General (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US63652504P | 2004-12-17 | 2004-12-17 | |
US74817805P | 2005-12-08 | 2005-12-08 | |
PCT/EP2005/013522 WO2006063837A2 (en) | 2004-12-17 | 2005-12-15 | Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1110512A1 true HK1110512A1 (en) | 2008-07-18 |
Family
ID=35810282
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK08101377.3A HK1110512A1 (en) | 2004-12-17 | 2008-02-05 | Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder |
Country Status (13)
Country | Link |
---|---|
US (1) | US7795385B2 (pt) |
EP (1) | EP1827476B1 (pt) |
JP (1) | JP4950903B2 (pt) |
CN (2) | CN102441157B (pt) |
AR (1) | AR052996A1 (pt) |
BR (1) | BRPI0519515A2 (pt) |
CA (1) | CA2590804C (pt) |
ES (1) | ES2434943T3 (pt) |
HK (1) | HK1110512A1 (pt) |
MX (1) | MX2007007238A (pt) |
NO (1) | NO20073696L (pt) |
TW (1) | TWI361694B (pt) |
WO (1) | WO2006063837A2 (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2006143601A (ja) * | 2004-11-16 | 2006-06-08 | Yamato Yakuhin Kk | 血液粘度低下剤 |
DE102007005580A1 (de) * | 2007-01-23 | 2008-07-24 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Arzneimittel zur Behandlung von Sepsis |
WO2010101990A1 (en) * | 2009-03-04 | 2010-09-10 | Duke University | Methods of treating lung disease and other inflammatory diseases |
CN103027915A (zh) * | 2011-09-29 | 2013-04-10 | 中国医学科学院基础医学研究所 | 氯喹治疗和氯丙嗪预防肺感染和损伤的用途 |
US20220002399A1 (en) * | 2018-09-11 | 2022-01-06 | University Of Maryland, Baltimore | Methods for decreasing influenza-induced lethality using gastrin-releasing peptide (grp) inhibitors or gastrin-releasing peptide receptor (grpr) antagonists |
CN115998724B (zh) * | 2023-03-28 | 2023-06-16 | 中国人民解放军军事科学院军事医学研究院 | 布洛芬在抗幻觉作用药物中的新用途 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992007830A2 (en) * | 1990-10-29 | 1992-05-14 | Pfizer Inc. | Oxindole peptide antagonists |
US5369094A (en) * | 1990-11-29 | 1994-11-29 | The Administrators Of The Tulane Educational Fund | Polypeptide bombesin antagonists |
US5244883A (en) | 1990-11-29 | 1993-09-14 | The Administrators Of The Tulane Educational Fund | Nonapeptide bombesin antagonists |
JPH07509223A (ja) * | 1992-04-30 | 1995-10-12 | アムジェン インコーポレイテッド | インターロイキン−1媒介疾患および腫瘍壊死因子媒介疾患の治療方法 |
US5620955A (en) * | 1993-06-18 | 1997-04-15 | Peptide Technologies Corporation | Bombesin receptor antagonists and uses thereof |
GB9322828D0 (en) * | 1993-11-05 | 1993-12-22 | Sandoz Ltd | Organic compounds |
JPH0853387A (ja) * | 1994-08-12 | 1996-02-27 | Sankyo Co Ltd | 新規化合物f−11263 |
US5750370A (en) * | 1995-06-06 | 1998-05-12 | Human Genome Sciences, Inc. | Nucleic acid encoding human endothlein-bombesin receptor and method of producing the receptor |
WO1998007718A1 (en) * | 1996-08-22 | 1998-02-26 | Warner-Lambert Company | Non-peptide bombesin receptor antagonists |
US20040127470A1 (en) * | 1998-12-23 | 2004-07-01 | Pharmacia Corporation | Methods and compositions for the prevention or treatment of neoplasia comprising a Cox-2 inhibitor in combination with an epidermal growth factor receptor antagonist |
GB2369117A (en) * | 2000-11-17 | 2002-05-22 | Warner Lambert Co | Bombesin receptor antagonists |
GB2369118A (en) * | 2000-11-17 | 2002-05-22 | Warner Lambert Co | Bombesin receptor antagonists |
WO2004060911A2 (en) * | 2002-12-30 | 2004-07-22 | Amgen Inc. | Combination therapy with co-stimulatory factors |
-
2005
- 2005-12-13 US US11/299,849 patent/US7795385B2/en not_active Expired - Fee Related
- 2005-12-15 WO PCT/EP2005/013522 patent/WO2006063837A2/en active Application Filing
- 2005-12-15 JP JP2007545953A patent/JP4950903B2/ja not_active Expired - Fee Related
- 2005-12-15 CN CN201110396520.5A patent/CN102441157B/zh not_active Expired - Fee Related
- 2005-12-15 CN CN2005800431853A patent/CN101090731B/zh not_active Expired - Fee Related
- 2005-12-15 BR BRPI0519515-2A patent/BRPI0519515A2/pt not_active IP Right Cessation
- 2005-12-15 ES ES05847549T patent/ES2434943T3/es active Active
- 2005-12-15 EP EP05847549.2A patent/EP1827476B1/en active Active
- 2005-12-15 MX MX2007007238A patent/MX2007007238A/es active IP Right Grant
- 2005-12-15 CA CA2590804A patent/CA2590804C/en not_active Expired - Fee Related
- 2005-12-15 TW TW094144549A patent/TWI361694B/zh not_active IP Right Cessation
- 2005-12-16 AR ARP050105325A patent/AR052996A1/es unknown
-
2007
- 2007-07-17 NO NO20073696A patent/NO20073696L/no not_active Application Discontinuation
-
2008
- 2008-02-05 HK HK08101377.3A patent/HK1110512A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
AR052996A1 (es) | 2007-04-18 |
TW200635602A (en) | 2006-10-16 |
NO20073696L (no) | 2007-09-07 |
WO2006063837A3 (en) | 2007-02-08 |
CA2590804C (en) | 2015-12-22 |
WO2006063837A8 (en) | 2007-08-30 |
MX2007007238A (es) | 2007-07-11 |
JP2008538098A (ja) | 2008-10-09 |
ES2434943T3 (es) | 2013-12-18 |
CN101090731A (zh) | 2007-12-19 |
CN102441157A (zh) | 2012-05-09 |
US20060160744A1 (en) | 2006-07-20 |
TWI361694B (en) | 2012-04-11 |
CN101090731B (zh) | 2012-08-08 |
JP4950903B2 (ja) | 2012-06-13 |
CA2590804A1 (en) | 2006-06-22 |
US7795385B2 (en) | 2010-09-14 |
EP1827476B1 (en) | 2013-08-14 |
BRPI0519515A2 (pt) | 2009-02-25 |
WO2006063837A2 (en) | 2006-06-22 |
CN102441157B (zh) | 2014-05-21 |
EP1827476A2 (en) | 2007-09-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL178402A0 (en) | 1-amino-phthalazine derivatives, the preparation and the therapeutic use thereof | |
IL178390A0 (en) | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease | |
EP1786515A4 (en) | TREATMENT OF THE VEGETABLE NERVOUS SYSTEM | |
IL184425A0 (en) | Cxcr4 antagonists for the treatment of medical disorders | |
ZA200606056B (en) | Selected CGRP antagonists, methods for the production thereof and their use as medicaments | |
IL178815A0 (en) | The treatment of respiratory disease | |
IL183537A0 (en) | Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders | |
EP1985302A4 (en) | DRUGS FOR TUMOR THERAPY AND ITS USE | |
HK1091732A1 (en) | Use of modified cyclosporins for the treatment of hcv disorders | |
HK1166983A1 (zh) | 包含用於治療疾病或紊亂的化合物的固體形式,其組合物,及其用途 | |
ZA200703876B (en) | 2-amido -4-phenylthiazole derivatives, the preparation and therapeutic use thereof | |
IL182222A0 (en) | Treatment of bipolar disorders and associated symptoms | |
SI1863476T1 (sl) | Kombinacija antiholinergikov in antagonistov receptorja levkotriena za zdravljenje respiratornih bolezni | |
HK1110512A1 (en) | Use of bombesin/gastrin-releasing peptide antagonists for the treatment of inflammatory conditions, acute lung injury and bipolar disorder | |
IL187248A0 (en) | Novel mchr1 antagonists and their use for the treatment of mchr1 mediated conditions and disorders | |
IL180770A0 (en) | Oxopiperidine derivatives, preparation and therapeutic use thereof | |
GB0410399D0 (en) | The treatment of respiratory disease | |
IL174303A0 (en) | Chelerythrine, analogs thereof and their use in the treatment of bipolar disorder and other cognitive disorders | |
IL180797A0 (en) | Amino-tropane derivatives, preparation thereof and therapeutic use thereof | |
HK1079776A1 (en) | The synthesis of 1,3-dihydro-2h-3-benzazepin-2-onecompounds, and the use thereof | |
WO2009006246A8 (en) | Use of tight junction antagonists in the treatment of acute long injury and acute respiratory distress syndrome | |
WO2006016192A3 (en) | Combination therapy with nk3 receptor antagonists for the treatment of schizophrenia | |
GB0427568D0 (en) | Particle-size reduction apparatus, and the use thereof | |
TWI347845B (en) | Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same | |
EP2193789A4 (en) | USE OF 3,5-DIHYDROTOLUENE OR ITS DERIVATIVES IN THE PREPARATION OF MEDICINAL PRODUCTS OR FUNCTIONAL FOOD FOR THE TREATMENT OR PREVENTION OF DEPRESSION |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PC | Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee) |
Effective date: 20151215 |